Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.

doi:10.1093/carcin/bgs203

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.

Carcinogenesis - 1 Sept 2012

Gulhati Pat, Zaytseva Yekaterina Y, Valentino Joseph D, Stevens Payton D, Kim Ji Tae, Sasazuki Takehiko, Shirasawa Senji, Lee Eun Y, Weiss Heidi L, Dong Jianli, Gao Tianyan, Evers B Mark

Abstract excerpt

Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC). The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating tha...

Topics

Animals
Antineoplastic Agents
Apoptosis
Benzenesulfonates
Cell Cycle
Cell Line, Tumor
Class I Phosphatidylinositol 3-Kinases
Colorectal Neoplasms
Drug Synergism
Humans
MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Male

Mechanistic Target of Rapamycin Complex 1

Mice

Multiprotein Complexes

Mutation

Niacinamide

Phenylurea Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 22696593
DOI: 10.1093/carcin/bgs203
PMCID: PMC3514899

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-22696593-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.PMID 22696593Read ↗

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.Semantic proximity Read ↗

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.Semantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.Semantic proximity Read ↗

Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.Semantic proximity Read ↗

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity Read ↗

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Semantic proximity Read ↗

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Semantic proximity Read ↗

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.